Insmed Inc
NASDAQ:INSM
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
22
79.01
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Insmed Inc
Insmed Inc
Net Change in Cash
Insmed Inc
Net Change in Cash Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Change in Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Insmed Inc
NASDAQ:INSM
|
Net Change in Cash
$633.9m
|
CAGR 3-Years
30%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
55%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Net Change in Cash
-$6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-17%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Change in Cash
-$669m
|
CAGR 3-Years
57%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Change in Cash
-$25.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-116%
|
CAGR 10-Years
-19%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Change in Cash
-$5.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Change in Cash
-$148.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Insmed Inc
Glance View
Insmed Inc. is a biopharmaceutical company on a mission to transform the lives of patients with severe and rare diseases, particularly those related to lung and infectious conditions. Founded in 1988, Insmed has carved out a niche in the biotechnology landscape with its innovative approach to drug development. The company's flagship product, Arikayce, has gained approval for the treatment of nontuberculous mycobacterial (NTM) lung infections, demonstrating its commitment to addressing unmet medical needs. With a robust pipeline of therapeutic candidates focusing on rare diseases, Insmed is not just another player in the biopharma space; it is dedicated to solving complex health challenges where conventional therapies have fallen short. Investors should take note of Insmed’s strategic direction and strong market position. The company is actively expanding its reach through ongoing clinical trials for its next generation therapies, which aim to target diseases with limited treatment options. With a solid financial foundation and partnerships that bolster its research capabilities, Insmed is poised for growth. As healthcare organizations increasingly prioritize personalized medicine and innovative treatments, Insmed's willingness to tackle rare conditions places it on a promising trajectory. For investors, this represents an opportunity not just in terms of potential financial returns, but also in contributing to advancements in healthcare that can have a meaningful impact on patients' lives.
See Also
What is Insmed Inc's Net Change in Cash?
Net Change in Cash
633.9m
USD
Based on the financial report for Jun 30, 2024, Insmed Inc's Net Change in Cash amounts to 633.9m USD.
What is Insmed Inc's Net Change in Cash growth rate?
Net Change in Cash CAGR 10Y
55%
Over the last year, the Net Change in Cash growth was 222%. The average annual Net Change in Cash growth rates for Insmed Inc have been 30% over the past three years , and 55% over the past ten years .
You don't have any saved screeners yet
